Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment

Archive ouverte

Eimer, Johannes | Fréchet-Jachym, Mathilde | Le Dû, Damien | Caumes, Eric | El-Helali, Najoua | Marigot-Outtandy, Dhiba | Mechai, Frédéric | Peytavin, Gilles | Pourcher, Valérie | Rioux, Christophe | Yazdanpanah, Yazdan | Robert, Jérôme | Guglielmetti, Lorenzo | Aubry, Alexandra | Bonnet, Isabelle | Morel, Florence | Veziris, Nicolas | Lecorché, Emmanuel | Mougari, Faiza | Andrejak, Claire | Bourgarit, Anne | Klement, Elise | Rivoire, Bénédicte | Thouvenin, Guillaume | Tunesi, Simone | Wicky, Marie | Jaspard, Marie | Alauzet, Corentine | Escaut, Lelia | Ellis-Corbet, Sophie | Bernard, Christine | Roux, Anne-Laure

Edité par CCSD ; Oxford University Press (OUP) -

International audience. Abstract Background Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to predict drug toxicity is scarce. This study aimed to evaluate the association of linezolid trough concentrations with severe toxicity. Methods We retrospectively assessed consecutive patients started on linezolid for MDR tuberculosis between 2011 and 2017. The primary outcome was severe mitochondrial toxicity (SMT) due to linezolid, defined as neurotoxicity or myelotoxicity leading to drug discontinuation. The impact of plasma linezolid trough concentrations >2 mg/L was assessed in multivariate Cox proportional hazards models including time-varying covariates. Results SMT occurred in 57 of 146 included patients (39%) at an incidence rate of 0.38 per person-year (95% confidence interval, .30–.49). A maximum linezolid trough concentration >2 mg/L was detected in 52 patients (35.6%), while the mean trough concentration was >2 mg/L in 22 (15%). The adjusted hazard ratio for SMT was 2.35 (95% confidence interval, 1.26–4.38; P = .01) in patients with a mean trough concentration >2 mg/L and 2.63 (1.55–4.47; P < .01) for SMT after the first detection of a trough concentration >2 mg/L. In an exploratory analysis, higher maximum trough concentrations were dose-dependently associated with toxicity, while lowering elevated trough concentrations did not restore baseline risk. Conclusions Linezolid trough concentrations >2 mg/L are strongly associated with the development of severe treatment-emergent toxicity in patients treated for MDR tuberculosis. Pending further prospective evidence, an individual risk-benefit assessment on the continuation of linezolid treatment is warranted in any patient with trough concentrations >2 mg/L.

Consulter en ligne

Suggestions

Du même auteur

Increased linezolid plasma concentrations are associated with the development of severe toxicity in MDR-TB treatment.

Archive ouverte | Eimer, Johannes | CCSD

Auteurs : the LZDM group. International audience. Abstract Background Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic dru...

Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium

Archive ouverte | Guglielmetti, Lorenzo | CCSD

International audience

Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis

Archive ouverte | Guglielmetti, Lorenzo | CCSD

for the French MDR-TB Management Group9. International audience. Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis (MDR-TB), is recommended for a duration of 24 weeks. There...

Chargement des enrichissements...